Shots:
- OrsoBio has reported topline P-IIa PoC trial data assessing TLC-2716 (6 or 12mg, QD, PO) vs PBO in 30 overweight pts with severe hypertriglyceridemia & metabolic dysfunction–associated steatotic liver disease (MASLD)
- The study met its 1EP, showing statistically significant reductions in fasting triglycerides & remnant cholesterol, plus improved liver fat by MRI-PDFF, with stronger lipid reductions at both doses, especially in pts with baseline triglycerides ≥500 mg/dL
- Across the study population, TLC-2716 also showed consistent reductions in multiple atherogenic lipids, incl. total cholesterol, non-HDL cholesterol, & VLDL cholesterol
Ref: Businesswire | Image: OrsoBio | Press Release
Related News: Ionis Highlights P-III (CORE & CORE2) Trials Results of Olezarsen for Severe Hypertriglyceridemia (sHTG) at AHA 2025
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
